A Phase I/II Trial of an Oral MTOR Protein Kinase Inhibitor (Everolimus, RAD001) in Combination With an Oral EGFR Tyrosine Kinase Inhibitor (Erlotinib, TarcevaTM) In Patients With Metastatic Breast Cancer. The gene discussed is WEE1; the disease is breast cancer.